Stock:
Symbol Lookup
Register | Login My Watchlist | My Account | Logout
History
to View Your Portfolio

Pre Market | Dow Jones | Gold | Newsletters | Learn


Sequenom - SQNM - 2012 was a year of remarkable progress for Sequenom

Monday, January 7, 2013 11:17 AM
Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative diagnostic testing and genetic analysis solutions, announced preliminary highlights of the Company's 2012 performance and accomplishments. SQNM - Initial 2012 Performance Results (unaudited)
  • Total revenue of approximately $89 million, growth of approximately 59 percent year-over-year for 2012
  • Diagnostic services revenues of approximately $46 million, compared to $8.3 million in 2011.  Diagnostic services revenues continue to be recorded primarily as cash is received
  • Sales in the Genetic Analysis business of approximately $43 million
  • More than 92,000 total prenatal and retinal diagnostic tests accessioned during the year
  • Strong increases in the adoption rate and sales of Sequenom Center for Molecular Medicine's (Sequenom CMM) MaterniT21 PLUS lab-developed test (LDT):
    • More than 60,000 MaterniT21 PLUS tests accessioned in 2012
    • An annualized run rate of more than 120,000 MaterniT21 PLUS tests accessioned at the end of 2012
    • Approximately 56 million lives under coverage with growing number of payor contracts
    • Continued reimbursement as an out-of-network laboratory from large commercial payors
  • Total cash, cash equivalents, and marketable securities as of December 31, 2012 were approximately $176 million
  • Cash burn of approximately $17 million for the fourth quarter of 2012
"2012 was a year of remarkable progress for Sequenom.  The rapid adoption of the Sequenom CMM's MaterniT21 PLUS by the OB/GYN physician community far exceeded the Company's internal goal and the estimates of industry analysts.  The joint recommendation by the American College of Obstetricians and Gynecologists (ACOG) and the Society of Maternal and Fetal Medicine (SMFM) for the use of noninvasive prenatal tests (NIPT) such as the MaterniT21 PLUS in high risk pregnancies provided an additional validation for this technology.  The company also exceeded the majority of its other goals as it established Sequenom CMM as a leader in the prenatal testing market," said Harry F. Hixson, Jr, Ph.D., Chairman and CEO of Sequenom.  "We look forward to the continued growth of the MaterniT21 PLUS LDT in 2013 and the corresponding increase in test capacity.  We plan to work with national and regional payors to establish additional contracts facilitating the availability of the MaterniT21 PLUS LDT to high-risk pregnant women throughout the United States." About Sequenom - SQNM Sequenom, Inc. (SQNM) is a life sciences company committed to improving healthcare through revolutionary genetic analysis solutions. Sequenom develops innovative technology, products and diagnostic tests that target and serve discovery and clinical research, and molecular diagnostics markets. SQNM was founded in 1994 and is headquartered in San Diego, California.
PRINT

FREE Options Trading Lessons
I'll show you how to unlock HUGE Gains with Options Trading
Let's make 2016 the year you get RICH!

Latest Headlines

Stocks dumped for safe havens as bank fears flare Stocks dumped for safe havens as bank fears flare
SYDNEY (Reuters) - Asian share markets were scorched on Tuesday as stability concerns put a torch to European bank stocks and sent investors stampeding to only the safest of safe haven assets. As ...
Japan Aso warns against yen rise, describes moves as 'rough'Japan Aso warns against yen rise, describes moves as 'rough'
TOKYO (Reuters) - Japanese Finance Minister Taro Aso on Tuesday warned against a recent rise in the yen and said he would continue to closely monitor the currency market. "It`s clear that recent mov...
Risk aversion drives yen to one-year highs vs USDRisk aversion drives yen to one-year highs vs USD
SYDNEY (Reuters) - The yen held at its highest in over a year against the dollar early on Tuesday, having soared broadly as a selloff in European and U.S. stocks stoked demand for the safe-haven cur...
Now it is Tesla's turn to confront the bearsNow it is Tesla's turn to confront the bears
SAN FRANCISCO (Reuters) - Tesla Motors Inc faces a pivotal moment Wednesday in its fight to convince skeptical investors that it can still win against traditional auto makers in the competition to r...
Japan's top FX diplomat says watching for any excessive yen moves: NikkeiJapan's top FX diplomat says watching for any excessive yen moves: Nikkei
TOKYO (Reuters) - Japan`s top currency diplomat Masatsugu Asakawa said he was watching daily exchange-rate moves carefully to check for excessive volatility, the daily Nikkei newspaper reported. "Bu...

Loading Headlines...
 

Stock Market

Track the stock market today with the latest news and information on all things investing! Watch your stocks perform throughout the day and watch the breaking stock market news.

Feedback | disclaimer | privacy policy

Stock Market News

The Stock Market is ever changing. Keep up on your stock market news.

Stock Market Newsletters

Read up on your favorite stock market newsletters.

{localized={en_US=Terry}, preferredLocale={country=US, language=en}} {localized={en_US=Scott}, preferredLocale={country=US, language=en}}

Terry Scott
CEO of StockMarketWatch

View Profile


Learn the Stock Market

Sharper your stock trading skills with our stock market education section.

Be a Better
Trader, Today
arrow
PreMarket PRO Our New Streaming Realtime Pre-Market Product -- Click Here to Learn More